108 related articles for article (PubMed ID: 33469839)
1. PD-1 and PD-L2 expression predict relapse risk and poor survival in patients with stage III colorectal cancer.
Zengin M; Zergeroğlu S; Okcu O; Benek S
Cell Oncol (Dordr); 2021 Apr; 44(2):423-432. PubMed ID: 33469839
[TBL] [Abstract][Full Text] [Related]
2. Impact of sidedness of colorectal cancer on tumor immunity.
Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
[TBL] [Abstract][Full Text] [Related]
3. Increasing the expression of programmed death ligand 2 (PD-L2) but not 4-1BB ligand in colorectal cancer cells.
Shakerin P; Sedighi Moghadam B; Baghaei K; Safaei Naraghi Z; Kamyab Hesari K; Asadzadeh Aghdaei H; Shokouhi Shoormasti R; Fazeli MS; Nourizadeh M
Mol Biol Rep; 2020 Aug; 47(8):5689-5697. PubMed ID: 32661872
[TBL] [Abstract][Full Text] [Related]
4. The Prognostic Significance of the Tumor-infiltrating Programmed Cell Death-1
Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Matsutani S; Hirakawa K; Ohira M
Anticancer Res; 2017 Aug; 37(8):4165-4172. PubMed ID: 28739701
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy.
Huang KC; Chiang SF; Chen TW; Chen WT; Yang PC; Ke TW; Chao KSC
Sci Rep; 2020 Dec; 10(1):22330. PubMed ID: 33339860
[TBL] [Abstract][Full Text] [Related]
6. Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer.
Enkhbat T; Nishi M; Takasu C; Yoshikawa K; Jun H; Tokunaga T; Kashihara H; Ishikawa D; Shimada M
Anticancer Res; 2018 Jun; 38(6):3367-3373. PubMed ID: 29848685
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and clinicopathological value of PD-L2 in lung cancer: A meta-analysis.
Lin X; Lin K; Lin C; Liu T; Ba M; Tang Y; Wang J; Zhou L; Wang J; Xiao C
Int Immunopharmacol; 2021 Feb; 91():107280. PubMed ID: 33370681
[TBL] [Abstract][Full Text] [Related]
8. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
[TBL] [Abstract][Full Text] [Related]
10. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
Cancer Med; 2019 Mar; 8(3):1124-1134. PubMed ID: 30659749
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer.
Takamori S; Takada K; Azuma K; Jogo Y; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Akamine T; Toyokawa G; Hirai F; Tagawa T; Okamoto I; Nakanishi Y; Kawahara A; Akiba J; Oda Y; Maehara Y
Anticancer Res; 2018 Oct; 38(10):5903-5907. PubMed ID: 30275217
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and Prognostic Analysis of PD-L1 and PD-L2 Expression in Surgically Resected Primary Tongue Squamous Cell Carcinoma.
Furukawa K; Kawasaki G; Yoshida T; Umeda M
Anticancer Res; 2021 Jan; 41(1):101-111. PubMed ID: 33419803
[TBL] [Abstract][Full Text] [Related]
14. Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors.
Pinto N; Park JR; Murphy E; Yearley J; McClanahan T; Annamalai L; Hawkins DS; Rudzinski ER
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28488345
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological significance and prognostic implication of programmed death-1 ligand 2 expression in colorectal cancer.
Pyo JS; Son BK; Chung KH; Oh IH
Int J Biol Markers; 2019 Sep; 34(3):276-283. PubMed ID: 31337259
[TBL] [Abstract][Full Text] [Related]
16. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy.
Tanaka K; Miyata H; Sugimura K; Kanemura T; Hamada-Uematsu M; Mizote Y; Yamasaki M; Wada H; Nakajima K; Takiguchi S; Mori M; Doki Y; Tahara H
Cancer Sci; 2016 Jun; 107(6):726-33. PubMed ID: 27015293
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer.
Watson MM; Lea D; Gudlaugsson E; Skaland I; Hagland HR; Søreide K
Cancer Immunol Immunother; 2020 Aug; 69(8):1627-1637. PubMed ID: 32314040
[TBL] [Abstract][Full Text] [Related]
18. PD-L2: A prognostic marker in chromophobe renal cell carcinoma?
Erlmeier F; Weichert W; Autenrieth M; Wiedemann M; Schrader AJ; Hartmann A; Ivanyi P; Steffens S
Med Oncol; 2017 May; 34(5):71. PubMed ID: 28353093
[TBL] [Abstract][Full Text] [Related]
19. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Impact of PD-1 and Tim-3 Expression in Tumor Tissue in Stage I-III Colorectal Cancer.
Kuai W; Xu X; Yan J; Zhao W; Li Y; Wang B; Yuan N; Li Z; Jia Y
Biomed Res Int; 2020; 2020():5294043. PubMed ID: 32509862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
